Last ¥1,623 JPY
Change Today +6.00 / 0.37%
Volume 2.8M
4568 On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
OTC US
Frankfurt
As of 1:00 AM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

daiichi sankyo co ltd (4568) Snapshot

Open
¥1,633
Previous Close
¥1,617
Day High
¥1,634
Day Low
¥1,617
52 Week High
07/29/14 - ¥1,904
52 Week Low
01/16/15 - ¥1,556
Market Cap
1.2T
Average Volume 10 Days
5.0M
EPS TTM
--
Shares Outstanding
709.0M
EX-Date
03/27/15
P/E TM
--
Dividend
¥60.00
Dividend Yield
3.70%
Current Stock Chart for DAIICHI SANKYO CO LTD (4568)

Related News

No related news articles were found.

daiichi sankyo co ltd (4568) Related Businessweek News

No Related Businessweek News Found

daiichi sankyo co ltd (4568) Details

Daiichi Sankyo Company, Limited engages in the research, development, manufacture, import, sale, and marketing of pharmaceutical products in Japan and internationally. The company’s product portfolio includes generic pharmaceuticals, vaccines, and over-the-counter (OTC) medicines. Its principal products include Olmesartan, an anti-hypertensive agent; Prasugrel, an antiplatelet agent; Edoxaban, an anticoagulant; Memary and Donepezil for the treatment of alzheimer’s disease; Nexium for treating reflux esophagitis; Pralia for osteoporosis; Tenelia for treatment for type 2 diabetes mellitus; and ActHIB, a haemophilus b conjugate vaccine, as well as Denosumab to treat and prevent various bone disorders, including osteoporosis and bone metastases. The company’s products OTC comprise Loxonin S, an analgesic and anti-inflammatory drug; Transino II, a drug for the improvement of spots; and Traful Ointment for stomatitis treatment. It also markets therapies in hypertension, dyslipidemia, and bacterial infections, as well as treatments for thrombotic disorders. In addition, the company researches and develops therapies in oncology and cardiovascular-metabolic diseases, including biologics. Further, it manufactures and sells cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates, as well as pharmaceuticals and drugs for animals. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Tokyo, Japan.

32,791 Employees
Last Reported Date: 06/23/14
Founded in 1899

daiichi sankyo co ltd (4568) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

daiichi sankyo co ltd (4568) Key Developments

U.S. FDA Approves Daiichi Sankyo's Once-Daily Savaysa (Edoxaban) Tablets for Reduction of Stroke Risk in Non-Valvular Atrial Fibrillation and for the Treatment of Venous Thromboembolism

Daiichi Sankyo Company, Limited announced that the U.S. Food and Drug Administration (FDA) has approved SAVAYSA (edoxaban) Tablets, an oral, once-daily selective factor Xa-inhibitor, to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF). In ENGAGE AF-TIMI 48, SAVAYSA was non-inferior to warfarin in the overall study population for the primary efficacy endpoint of stroke or SE. As stated in the U.S. label, SAVAYSA should not be used in NVAF patients with creatinine clearance (CrCL) levels greater than 95 mL/min because in that population there is an increased risk of ischemic stroke compared to warfarin. Patients with CrCL less than or equal to 95 mL/min represented 77% of the patients studied. In those patients, SAVAYSA 60 mg (30 mg dose reduced) reduced the risk of stroke and SE when compared to warfarin (hazard ratio [HR], 0.68; 95% confidence interval [CI], 0.55 to 0.84), and the rates of cardiovascular death with SAVAYSA and warfarin were 2.95% per year vs. 3.59% per year, respectively. The FDA also approved SAVAYSA for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant.

Nolan Auerbach & White Announces Five-Year-Long Civil False Claims Act Case against Daiichi Sankyo

Nolan Auerbach & White announced the successful resolution of its client's five-year-long civil False Claims Act case against Daiichi Sankyo. The qui tam case was brought in March 2010 by client Kathy Fragoules, a former Daiichi Sankyo sales representative. Ms. Fragoules alleged that Daiichi Sankyo had various programs utilized by its sales representatives to induce physicians to use its pharmaceuticals, including Welchol, Azor, Benicar, and Benicar HCT. According to her qui tam complaint, these inducements caused physicians to prescribe Daiichi Sankyo pharmaceuticals for government healthcare program beneficiaries in violation of the Anti-Kickback Statute. Daiichi Sankyo has agreed to pay $39,015,770 plus interest to resolve Ms. Fragoulesâ s qui tam lawsuit.

U.S. FDA Approves Daiichi Daiichi Sankyo Company, Limited's SAVASA Tablets

Daiichi Sankyo Company, Limited announced that the U.S. Food and Drug Administration (FDA) has approved SAVAYSATM (edoxaban) Tablets, an oral, once-daily selective factor Xa-inhibitor, to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF). In ENGAGE AF-TIMI 48, SAVAYSA was non-inferior to warfarin in the overall study population for the primary efficacy endpoint of stroke or SE. As stated in the U.S. label, SAVAYSA should not be used in NVAF patients with creatinine clearance (CrCL) levels greater than 95 mL/min because in that population there is an increased risk of ischemic stroke compared to warfarin. Patients with CrCL less than or equal to 95 mL/min represented 77% of the patients studied. In those patients, SAVAYSA 60 mg (30 mg dose reduced) reduced the risk of stroke and SE when compared to warfarin (hazard ratio [HR], 0.68; 95% confidence interval [CI], 0.55 to 0.84), and the rates of cardiovascular death with SAVAYSA and warfarin were 2.95% per year vs. 3.59% per year, respectively.1 The FDA also approved SAVAYSA for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4568:JP ¥1,622.50 JPY +6.00

4568 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $7.11 USD +2.06
BioCryst Pharmaceuticals Inc $10.99 USD +0.29
BioMerieux €97.50 EUR +1.41
Infinity Pharmaceuticals Inc $15.29 USD +0.56
Ipsen SA €44.36 EUR +0.84
View Industry Companies
 

Industry Analysis

4568

Industry Average

Valuation 4568 Industry Range
Price/Earnings 13.7x
Price/Sales 0.9x
Price/Book 1.0x
Price/Cash Flow 13.8x
TEV/Sales 0.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAIICHI SANKYO CO LTD, please visit www.daiichisankyo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.